Czech Republic Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Czech Republic Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Czech Republic Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: The Czech Republic will continue to be one of the most attractive markets in the CEE region for pharmaceutical and healthcare investment. A strong economic outlook will be the driving factor behind growth, with plans to further increase access to healthcare; pharmaceutical sales are expected to increase over the coming years.

Headline Expenditure Projections

  • Pharmaceuticals: CZK78.83bn (USD3.01bn) in 2015 to CZK81.10bn (USD3.27bn) in 2016; +2.9% in local currency terms and +8.6 % in US dollar terms. Forecasts in line with last quarter.

  • Healthcare: CZK284.72bn (USD10.87bn) in 2015 to CZK292.53bn (USD11.79bn) in 2016; +2.7% in local currency terms and +8.4% in US dollar terms. Forecasts in line with last quarter.

Headline Pharmaceuticals & Healthcare Forecasts (Czech Republic 2014-2020)
2014 2015e 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 3.427 3.010 3.268 3.593 3.946 4.122 4.274
Pharmaceutical sales, % of GDP 1.80 1.77 1.72 1.67 1.63 1.61 1.58
Pharmaceutical sales, % of health expenditure 27.3 27.7 27.7 27.7 27.6 27.4 27.3
Health spending, USDbn 12.536 10.871 11.787 12.996 14.319 15.021 15.652

Risk/Reward Index

In Q2 2016, the Czech Republic RRI score has been upgraded slightly from the previous quarter to 63.4 out of 100. The Czech Republic is ranked as the second most attractive market to pharmaceutical investors in the Central and Eastern European (CEE) region within our RRI matrix. The Czech pharmaceutical market score is driven by high pharmaceutical expenditure per capita, an ageing population and a favourable urban-rural distribution, but dragged down by a challenging pricing and reimbursement environment.

Latest Updates

  • In January 2016, the Czech Republic was represented as one of 23 countries to participate in the first partnership forum for the European Union Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT).

  • In January 2016, the Association for Bohemian and Moravian Hospitals demanded a 10% annual pay rise for doctors and nurses to prevent their emigration.

  • In December 2015, the Czech Minister of Health announced plans to improve the population's access to healthcare services, including increased insurer coverage for certain treatments such as pneumococcal vaccinations for elderly citizens and proton beam treatment for certain cancer types.

BMI Economic View

The Czech Republic's economic outlook looks to be strong in comparison to its regional neighbours in the years ahead. The manufacturing and automobile sectors will continue to benefit from recovering eurozone demand and rising consumer confidence domestically.

BMI Political View

Although the Czech Republic will continue to act as an anchor of political stability in central Europe, its dispute with the EU over the reallocation of refugees will lead to mounting tensions. Strong economic growth and an expansionary fiscal policy will give the coalition government continued public support.

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Czech Republic 2011-2019)
17
Healthcare Market Forecast
18
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2011-2019)
21
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2011-2019)
21
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2011-2019)
22
Prescription Drug Market Forecast
23
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2011-2019)
24
Patented Drug Market Forecast
25
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2011-2019)
26
Generic Drug Market Forecast
27
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2011-2019)
27
OTC Medicine Market Forecast
28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Czech Republic 2011-2019)
29
Pharmaceutical Trade Forecast
30
Table: Pharmaceutical Trade Data And Forecasts (Czech Republic 2013-2019)
31
Table: Pharmaceutical Trade Data And Forecasts local currency (Czech Republic 2013-2019)
31
Key Risks To BMI's Forecast Scenario
32
Macroeconomic Forecasts
33
Economic Analysis
33
Industry Risk Reward Ratings
39
Central And Eastern Europe Risk/Reward Index - Q4 2015
39
Czech Republic - Risk/Reward Index
45
Rewards
45
Risks
45
Market Overview
46
Industry Trends And Developments
47
Epidemiology
47
Healthcare Sector
48
Table: Healthcare Resources (Czech Republic 2009-2014)
49
Table: Healthcare Personnel (Czech Republic 2009-2014)
50
Table: Healthcare Activity (Czech Republic 2009-2014)
50
Healthcare Insurance
50
Healthcare Reforms
51
Hospital Sector
54
Research & Development
55
Clinical Trials
56
Regulatory Development
58
Regulatory Regime
58
Intellectual Property Environment
58
Prescribing Rules
58
Pharmaceutical Advertising
59
Pricing Regime
59
Reimbursement Regime
60
Recent Pricing And Reimbursement Developments
61
Changes To VAT
63
Table: European VAT Rates On Medicines (%)
64
Electronic Tenders
65
Competitive Landscape
67
Pharmaceutical Sector
67
Foreign Industry
68
Pharmaceutical Wholesale
69
Pharmaceutical Retail Sector
69
Table: Retail Pharmacy Market Overview, 2006-2012
69
Company Profile
71
AstraZeneca
71
Bristol-Myers Squibb
73
GlaxoSmithKline
75
Novartis
78
Pfizer
81
Sanofi
83
Walmark
86
Zentiva (Sanofi)
90
Demographic Data
94
Demographic Forecast
94
Table: Population Headline Indicators (Czech Republic 1990-2025)
95
Table: Key Population Ratios (Czech Republic 1990-2025)
95
Table: Urban/Rural Population & Life Expectancy (Czech Republic 1990-2025)
96
Table: Population By Age Group (Czech Republic 1990-2025)
96
Table: Population By Age Group % (Czech Republic 1990-2025)
97
Glossary
99
Methodology
101
Pharmaceutical Expenditure Forecast Model
101
Healthcare Expenditure Forecast Model
101
Notes On Methodology
102
Risk/Reward Index Methodology
103
Index Overview
104
Table: Pharmaceutical Risk/Reward Index Indicators
104
Indicator Weightings
105

The Czech Republic Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Czech Republic Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Czech Republic pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Czech Republic, to test other views - a key input for successful budgeting and strategic business planning in the Czech pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Czech pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Czech Republic.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.